Compare Incyte Corporation (INCY) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Quantum Computing Inc — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Quantum Computing Inc trades at $8.3 (market cap $1.79B). The key difference: Incyte Corporation is far larger — about 12.9× Quantum Computing Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.
| INCY | QUBT | |
|---|---|---|
Market Cap | $23.11B | $1.79B |
Sector | Health | Technology |
52-Week High | $118.52 | $24.62 |
52-Week Low | $67.38 | $6.31 |
Enterprise Value | $19.13B | $803.83M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Quantum Computing Inc. (QUBT) trades at $7.92, up 1.54% today, while technical indicators signal a bearish trend. The company shows minimal revenue of $682,000 for 2025 with a net loss of $18.67 million, resulting in negative profit margins. Analysts maintain a bullish consensus with a $26 price target, citing potential from commercial backlog and policy support, despite ongoing cash burn and a recent legal investigation into corporate governance.
QUBT offers high-risk, high-reward potential driven by quantum computing commercialization prospects, but faces significant execution risks and financial instability. The stock's outlook hinges on revenue scaling and managing cash flow, with substantial downside if growth targets are missed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
